Modulight Spotlights: LASER-SHARP RESEARCH – January 2025
We are pleased to highlight this month a new study published in Cancer Immunology, Immunotherapy by Hisataka Kobayashi’s team at National Cancer Institute, NIH. They developed light-activated immunotherapy targeting a specific protein found on the surface of many cancer cells, called tissue factor. This therapy consists of antibody-photoabsorber conjugate that binds to cancer cell surface, and in response to near-infrared light, induces photochemical reaction that results in membrane destruction and immunogenic cell death. When this novel agent was activated with the ML7710 laser, it showed efficacy against various cancer cell types including pancreatic, oral, breast, and ovarian cancer. Based on these promising preclinical results, the therapy is a good candidate for clinical translation.
Modulight is very happy to be supporting this research. We would like to deliver our warmest congratulations to the research team!
#Laser-Sharp Research #CancerResearch #immunology #immunotherapy #targetedtherapies
About Modulight’s LASER-SHARP RESEARCH concept:
Laser-Sharp Research is a concept where our scientific board highlights cutting-edge scientific research articles from our customers. Important selection criteria are that Modulight and laser product are mentioned in the publication, the impact and relevance of the results, clinical translatability, as well as scientific quality of the journal. The nominated research groups will be rewarded to encourage the great work done.
Contact Us
Do you have questions or comments related to this LASER-SHARP RESEARCH nomination? Maybe your group has done significant research that your would like us to spotlight? Or would you like to request literature? Please drop us a line!